Samsung Biologics completes spin-off to strengthen its focus as a pure-play CDMO
Spin-off finalized within five months following board resolution Proposal approved in shareholders' meeting with 99.9% support Company to reaffirm its identity as a pure-play CDMO INCHEON, South Korea, Nov. 3, 2025 /PRNewswire/ -- Samsung Biologics...
Samsung Biologics reports third quarter 2025 financial results
Recorded Q3'25 consolidated revenue of KRW 1,660.2 billion Recorded Q3'25 consolidated operating profit of KRW 728.8 billion Delivered consistent performance through stable capacity ramp-up and strengthened global partnerships INCHEON, South Korea,...
Celltrion unveils strategic vision for advancing its innovative drug pipeline at the 43rd Annual J.P. Morgan Healthcare Conference
Celltrion unveils strategic roadmap for the first time outlining its innovative drug development strategy and its plan to submit 13 Investigational New Drug (IND) application by 2028 Company reinforces its commitment to a two-pillar growth strategy...